Preferences for conducting molecular testing in patients with chronic lymphocytic leukemia to guide treatment decisions based on evolving novel combination regimens used as frontline therapy.
EP. 1: Current Approaches to Assessing Patients With CLL
Drs Alexey Danilov and Anthony Mato highlight their preferences for diagnostic and prognostic testing when evaluating patients with chronic lymphocytic leukemia.
EP. 2: Prognostic Testing and Chemoimmunotherapy Use in CLL
The types of prognostic assays used to help determine candidacy for chemoimmunotherapy as frontline treatment for chronic lymphocytic leukemia.
EP. 3: Diagnostic Testing for Newly Diagnosed CLL
Recommendations for conducting imaging scans and biopsies to help guide the treatment of newly diagnosed chronic lymphocytic leukemia.
EP. 4: Repeat Prognostic Testing in CLL
Drs Alexey Danilov and Anthony Mato recommend when hematologists and oncologists should consider repeat molecular testing for patients with chronic lymphocytic leukemia.
EP. 5: Frontline Treatment Approaches in CLL
Drs Alexey Danilov and Anthony Mato review treatment options available for newly diagnosed chronic lymphocytic leukemia and describe decisions for monotherapy vs combination therapy.
EP. 6: Future Directions Treating CLL With Novel Therapy-Based Regimens
Considerations for using novel fixed-duration regimens and triplet therapy to treat patients with chronic lymphocytic leukemia.
EP. 7: MRD Testing in CLL
Circumstances for which MRD testing may be considered for patients with chronic lymphocytic leukemia.
EP. 8: Optimizing Testing Rates in CLL: Q&A
Drs Alexey Danilov and Anthony Mato respond to a variety of questions pertaining to the assessment and treatment of patients with chronic lymphocytic leukemia.
Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer